Prospective Study of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Concurrent With Individualized Radiotherapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

摘要: Purpose To establish the safety profile and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) concurrent with individualized radiotherapy (RT) in patients locally advanced or metastatic non–small-cell lung cancer (NSCLC). Patients Methods Between June 2007 January 2010, 26 Stage III/IV NSCLC were enrolled this prospective study. These treated EGFR-TKIs (gefitinib 250 mg erlotinib 150 mg, oral daily) RT curative intent. The thoracic plans individually designed on basis tumor size normal tissue volume constraints. All assessed for toxicity, 25 available efficacy. primary endpoints acute overall survival, median survival time. secondary included local control rate, time to progression, progression-free (PFS). Results Median gross volume, mean dose, V20 56 cm 3 , 8.6 Gy, 14%, respectively. radiation dose was 70 Gy at a margin (range, 42–82 Gy), biological equivalent 105 60–119 Gy). Acute skin, hematologic, esophageal, pulmonary toxicities acceptable manageable. Severe adverse events neutropenia (Grade 4, 4%) thrombocytopenia 8%), esophagitis 3, 4%), pneumonitis 4%). With follow-up 10.2 months, rate 96% achieved tumor. PFS, 6.3, 10.2, 21.8 1- 2-year PFS rates both 42%, 1-, 2-, 3-year 57%, 45%, 30%, Conclusion Concurrent shows favorable promising outcome, therefore serving as therapeutic option NSCLC.